- Home
- PHAT vs ZBIO Comparison
PHAT vs ZBIO Comparison
Compare PHAT & ZBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PHAT
- ZBIO
- Stock Information
- Founded
- PHAT 2018
- ZBIO 2019
- Country
- PHAT United States
- ZBIO United States
- Employees
- PHAT N/A
- ZBIO N/A
- Industry
- PHAT Biotechnology: Pharmaceutical Preparations
- ZBIO
- Sector
- PHAT Health Care
- ZBIO
- Exchange
- PHAT Nasdaq
- ZBIO NYSE
- Market Cap
- PHAT 339.8M
- ZBIO 389.2M
- IPO Year
- PHAT 2019
- ZBIO 2024
- Fundamental
- Price
- PHAT $3.96
- ZBIO $9.81
- Analyst Decision
- PHAT Strong Buy
- ZBIO Strong Buy
- Analyst Count
- PHAT 5
- ZBIO 7
- Target Price
- PHAT $22.50
- ZBIO $32.29
- AVG Volume (30 Days)
- PHAT 1.2M
- ZBIO 260.1K
- Earning Date
- PHAT 05-08-2025
- ZBIO 05-16-2025
- Dividend Yield
- PHAT N/A
- ZBIO N/A
- EPS Growth
- PHAT N/A
- ZBIO N/A
- EPS
- PHAT N/A
- ZBIO N/A
- Revenue
- PHAT $55,252,000.00
- ZBIO $5,000,000.00
- Revenue This Year
- PHAT $202.23
- ZBIO N/A
- Revenue Next Year
- PHAT $113.81
- ZBIO N/A
- P/E Ratio
- PHAT N/A
- ZBIO N/A
- Revenue Growth
- PHAT 8001.47
- ZBIO N/A
- 52 Week Low
- PHAT $3.81
- ZBIO $5.83
- 52 Week High
- PHAT $19.71
- ZBIO $26.25
- Technical
- Relative Strength Index (RSI)
- PHAT 37.83
- ZBIO N/A
- Support Level
- PHAT $3.87
- ZBIO N/A
- Resistance Level
- PHAT $5.09
- ZBIO N/A
- Average True Range (ATR)
- PHAT 0.59
- ZBIO 0.00
- MACD
- PHAT -0.10
- ZBIO 0.00
- Stochastic Oscillator
- PHAT 6.12
- ZBIO 0.00
About PHAT Phathom Pharmaceuticals Inc.
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection.
About ZBIO ZENAS BIOPHARMA INC
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them.